GlassScriptPhysician profile
Alfredo D Dally
NPI 1376588061
$3,507.33
in general payments reported to CMS, 2019-2025
27 companies · $960 in 2025
The $960 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $900 · 2020: $110 · 2021: $226 · 2022: $358 · 2023: $322 · 2024: $631 · 2025: $960.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,913.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,912.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,053.94 | 2024-2025 | Airsupra, Breztri |
| Janssen Pharmaceuticals, INC | $381.37 | 2019-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $346.35 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $246.17 | 2019-2024 | Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $204.30 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $194.90 | 2019-2025 | Ofev |
| Biotronik INC. | $174.77 | 2019 | |
| Lilly USA, LLC | $127.21 | 2019-2025 | Mounjaro |
| Dexcom, INC. | $125.19 | 2021-2023 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $113.14 | 2019-2025 | Rybelsus, Ozempic |
| Abbott Laboratories | $107.06 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Pfizer INC. | $55.57 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $45.58 | 2020-2021 | |
| Corcept Therapeutics | $44.75 | 2024 | Korlym |
| Amgen INC. | $41.06 | 2022-2023 | Repatha, Otezla |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.09 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $27.01 | 2023 | Rexulti |
| Ibsa Pharma INC. | $24.92 | 2025 | Tirosint, Licart, Flector |
| Ethicon US, LLC | $23.01 | 2020 | |
| Sunovion Pharmaceuticals INC. | $20.79 | 2021 | |
| Mannkind Corporation | $20.26 | 2023 | Afrezza |
| Cumberland Pharmaceuticals, INC. | $18.96 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $18.18 | 2025 | Zoryve |
| Allergan, INC. | $17.55 | 2019 | |
| Glaxosmithkline, LLC. | $16.02 | 2021 | |
| Amneal Pharmaceuticals LLC | $14.94 | 2021 | |
| Abbvie INC. | $14.24 | 2023 | Vraylar |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alfredo Dally listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.